CHRS: Strategic oncology focus drives revenue growth and key clinical milestones, with major data readouts ahead
A completed pivot to innovative oncology has positioned the company as both a commercial and clinical stage player, with LOQTORZI driving revenue and funding pipeline development. Key data readouts for tagmokitug and casdozokitug are expected by year-end, supported by robust biomarker strategies.Ba…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.